Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Japanese subjects, age at least 20 years at the time of signing informed consent~* Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening~* HbA1c (glycosylated haemoglobin) 7.0-11.0 % (both inclusive) by central laboratory analysis, with the aim of a median of 8.3%. When approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c below or equal to 8.3%; or when approximately 50% of the randomised subjects have a HbA1c below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%~* Body-mass index (BMI) above or equal to 20 kg/m\^2~* Subjects on stable therapy with one OAD (defined as unchanged medication and unchanged dose) for at least 60 days (metformin, a-GI, TZD, SU, SGLT2i or glinide) prior to screening according to approved Japanese labelling~Exclusion Criteria:~* Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness including gestational diabetes)~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening~* Anticipated initiation or change in concomitant medications in excess of 14 days known to affect weight or glucose metabolism~* Impaired liver function, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or above 2.5 times upper limit of normal~* Renal impairment estimated Glomerular Filtration Rate (eGFR) below 60mL/min/1.73m\^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)~* Screening calcitonin equal to or above 50 ng/L~* History of pancreatitis (acute or chronic)~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide OD (Type: EXPERIMENTAL): None
- Insulin degludec OD (Type: ACTIVE_COMPARATOR): None
- Liraglutide OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).